Ellex Medical Lasers Limited
The Adelaide, Australia -based Ellex Medical Lasers Limited (ASX: ELX) develops and commercialises products like ophthalmic lasers and devices that help eye surgeons to effectively diagnose and treat eye diseases. The company operates through a global network of over 50 distribution partners across Europe, the United States, the Middle East, Japan, South America etc.
Ellex has a market capitalisation of AUD 84.72 million, with approximately 143.6 million outstanding shares. With the close of the market trading on February 28th, 2019, the ELX stock’s last self-off price stood at AUD 0.550, down 6.78%, indicating an intra-day loss of AUD 0.040. Over the last six months, the stock performance has been moderate with a negative return yield of 9.23%. The scenario continued into 2019 as the stock has generated a negative YTD return yield of 11.94% as on 27 February.
The Group’s sales revenue grew by 9% to $ 41.6 million in the half year ended December 31st, 2018. This was driven by a surge in Ellex 2RT® revenue by 532% to $ 1.2 million and Ellex iTrack™ revenues by 24% to $ 6.5 million. Besides, the EBITDA loss also improved 12% on the prior corresponding period to $ 0.85 million. The company also reported reduction of 0.3% in net loss to $ 2.7 million.
Creso Pharma Limited
Creso Pharma Limited (ASX: CPH), established in 2015 and based in Sydney, develops and commercializes innovative pharmaceutical-grade cannabis and hemp derived products as for human and animal in a diverse range of markets.
Creso has a market capitalisation of AUD 52.16 million with approximately 51.49 million outstanding shares. With the close of the market session on February 28TH, the CPH stock’s last traded at a sell-off price of AUD 0.387, up 0.519%, indicating an intra-day gain of AUD 0.002. The stock has generated a negative YTD return of AUD 29.70% and the stock has been trending down by 34.75% over the past six months.
Recently, the company’s wholly owned subsidiary, Mernova Medical Ltd, has been sanctioned the License to cultivate cannabis at its Windsor facility in Nova Scotia, Canada. In addition, Creso also entered into a collaboration agreement with Hempmate AG, Switzerland to strengthen its presence in the European countries and Burleigh Heads Cannabis Pty Ltd to launch its medicinal cannabis products in Australia. At the end of the quarter ended December 2018, the company had net cash and cash equivalents of AUD 6.379 million.
Bionomics Limited (ASX: BNO), a clinical-stage biopharmaceutical company based in Thebarton, Australia, is engaged in the research and development of novel drug candidates for the treatment of central nervous system disorders and cancer in France, Australia and the United States.
Bionomics has market cap of AUD 108.94 million and approximately 544.69 million volume of outstanding shares. At the end of the market session on February 28, the BNO stock closed at a sell-off price of AUD 0.240, up 20%, indicating an intra-day gain of AUD 0.040. The stock performance has been excellent since the onset of the new year with a positive YTD return of 86.05%.
At the end of the half year ended December 31st, 2018, the company reported a strong position of $ 27.35 million and revenue for the period was posted at around $ 5.29 million, down on $ 7.168 million in the prior corresponding period. Besides, the net operating and investing cash outflows decreased by 48.8% to $ 6.30 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.